• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

伊朗的乳腺癌状况：1998年至2014年间3010例病例的统计分析

Breast Cancer Status in Iran: Statistical Analysis of 3010 Cases between 1998 and 2014.

作者信息

Akbari Mohammad Esmaeil, Sayad Soheila, Sayad Saed, Khayamzadeh Maryam, Shojaee Leila, Shormeji Zeynab, Amiri Mojtaba

机构信息

Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Department of Surgery, Firoozgar Clinical Research Development Center, Iran University of Medical Sciences, Tehran, Iran.

出版信息

Int J Breast Cancer. 2017;2017:2481021. doi: 10.1155/2017/2481021. Epub 2017 Nov 1.

DOI:10.1155/2017/2481021
PMID:29201466
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5671722/
Abstract

BACKGROUND

Breast cancer is the 5th leading cause of cancer death in Iranian women. This study analyzed 3010 women with breast cancer that had been referred to a cancer research center in Tehran between 1998 and 2014.

METHODS

In this retrospective study, we analyzed 3010 breast cancer cases with 32 clinical and paraclinical attributes. We checked the data quality rigorously and removed any invalid values or records. The method was data mining (problem definition, data preparation, data exploration, modeling, evaluation, and deployment). However, only the descriptive analyses' results of the variables are presented in this article. To our knowledge, this is the most comprehensive study on breast cancer status in Iran.

RESULTS

A typical Iranian breast cancer patient has been a 40-50-year-old married woman with two children, who has a high school diploma and no history of abortion, smoking, or diabetes. Most patients were estrogen and progesterone receptor positive, human epidermal growth factor (HER) negative, and P53 negative. Most cases were detected in stage 2 with intermediate grade.

CONCLUSION

This study revealed original findings which can be used in national policymaking to find the best early detection method and improve the care quality and breast cancer prevention in Iran.

摘要

背景

乳腺癌是伊朗女性癌症死亡的第五大主要原因。本研究分析了1998年至2014年间转诊至德黑兰一家癌症研究中心的3010例乳腺癌女性患者。

方法

在这项回顾性研究中，我们分析了3010例具有32种临床和副临床特征的乳腺癌病例。我们严格检查了数据质量，去除了任何无效值或记录。方法是数据挖掘（问题定义、数据准备、数据探索、建模、评估和部署）。然而，本文仅呈现变量的描述性分析结果。据我们所知，这是关于伊朗乳腺癌状况最全面的研究。

结果

典型的伊朗乳腺癌患者是一名40至50岁、已婚、育有两个孩子、具有高中学历且无流产、吸烟或糖尿病史的女性。大多数患者雌激素和孕激素受体呈阳性，人表皮生长因子（HER）呈阴性，P53呈阴性。大多数病例在2期被检测出，分级为中级。

结论

本研究揭示了一些原始发现，可用于国家政策制定，以找到最佳的早期检测方法，并提高伊朗乳腺癌的护理质量和预防水平。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/de46a3cd4c75/IJBC2017-2481021.031.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/8237a7b69039/IJBC2017-2481021.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/20a4ff8401ca/IJBC2017-2481021.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/6e121e9627fc/IJBC2017-2481021.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/a4f884646aa2/IJBC2017-2481021.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/b6369a539a28/IJBC2017-2481021.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/3bcb69cc73b4/IJBC2017-2481021.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/939b019d542e/IJBC2017-2481021.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/450e84a97d3d/IJBC2017-2481021.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/f1af38faf3ce/IJBC2017-2481021.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/147392dc4bce/IJBC2017-2481021.011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/81f097803c4a/IJBC2017-2481021.012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/02e2fec7126d/IJBC2017-2481021.013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/79c445024fa2/IJBC2017-2481021.014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/8d02ef513e3e/IJBC2017-2481021.015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/9b350bf4f094/IJBC2017-2481021.016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/0e074c386e45/IJBC2017-2481021.017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/ff50b95a7ed6/IJBC2017-2481021.018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/075ea9b22f64/IJBC2017-2481021.019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/f74bdf232731/IJBC2017-2481021.021.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/5ce83e14811f/IJBC2017-2481021.022.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/d885f330e3d6/IJBC2017-2481021.023.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/7d4916c8846b/IJBC2017-2481021.024.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/4666099a45cb/IJBC2017-2481021.025.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/a465449a4d8f/IJBC2017-2481021.027.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/eed1aa664105/IJBC2017-2481021.029.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/de46a3cd4c75/IJBC2017-2481021.031.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/8237a7b69039/IJBC2017-2481021.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/20a4ff8401ca/IJBC2017-2481021.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/6e121e9627fc/IJBC2017-2481021.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/a4f884646aa2/IJBC2017-2481021.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/b6369a539a28/IJBC2017-2481021.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/3bcb69cc73b4/IJBC2017-2481021.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/939b019d542e/IJBC2017-2481021.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/450e84a97d3d/IJBC2017-2481021.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/f1af38faf3ce/IJBC2017-2481021.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/147392dc4bce/IJBC2017-2481021.011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/81f097803c4a/IJBC2017-2481021.012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/02e2fec7126d/IJBC2017-2481021.013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/79c445024fa2/IJBC2017-2481021.014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/8d02ef513e3e/IJBC2017-2481021.015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/9b350bf4f094/IJBC2017-2481021.016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/0e074c386e45/IJBC2017-2481021.017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/ff50b95a7ed6/IJBC2017-2481021.018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/075ea9b22f64/IJBC2017-2481021.019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/f74bdf232731/IJBC2017-2481021.021.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/5ce83e14811f/IJBC2017-2481021.022.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/d885f330e3d6/IJBC2017-2481021.023.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/7d4916c8846b/IJBC2017-2481021.024.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/4666099a45cb/IJBC2017-2481021.025.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/a465449a4d8f/IJBC2017-2481021.027.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/eed1aa664105/IJBC2017-2481021.029.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78b/5671722/de46a3cd4c75/IJBC2017-2481021.031.jpg

相似文献

1
Breast Cancer Status in Iran: Statistical Analysis of 3010 Cases between 1998 and 2014.伊朗的乳腺癌状况：1998年至2014年间3010例病例的统计分析
Int J Breast Cancer. 2017;2017:2481021. doi: 10.1155/2017/2481021. Epub 2017 Nov 1.
2
Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.用于指导早期乳腺癌女性辅助化疗决策的基因表达谱分析：基于证据的经济分析
Ont Health Technol Assess Ser. 2010;10(23):1-57. Epub 2010 Dec 1.
3
Mutation Screening of BRCA Genes in 10 Iranian Males with Breast Cancer.10例伊朗男性乳腺癌患者BRCA基因的突变筛查
Int J Mol Cell Med. 2016 Spring;5(2):114-22. Epub 2016 May 9.
4
Survival Rate and Prognostic Factors among Iranian Breast Cancer Patients.伊朗乳腺癌患者的生存率及预后因素
Iran J Public Health. 2020 Feb;49(2):341-350.
5
Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: A tertiary care center experience.南印度乳腺癌患者的激素受体状态（雌激素受体、孕激素受体）、人表皮生长因子-2及p53：一家三级护理中心的经验
Indian J Med Paediatr Oncol. 2015 Apr-Jun;36(2):117-22. doi: 10.4103/0971-5851.158844.
6
Pathological Characteristics of Triple-Negative Breast Cancer at Main Referral Teaching Hospital, April 2014 to April 2015, Tehran, Iran.2014年4月至2015年4月伊朗德黑兰主要转诊教学医院三阴性乳腺癌的病理特征
Int J Hematol Oncol Stem Cell Res. 2016 Oct 1;10(4):200-205.
7
Treatment and prognosis of breast cancer patients with brain metastases according to intrinsic subtype.根据内在亚型对脑转移乳腺癌患者的治疗及预后
Jpn J Clin Oncol. 2014 Nov;44(11):1025-31. doi: 10.1093/jjco/hyu126. Epub 2014 Aug 25.
8
Triple-negative breast cancer survival in Iranian patients.伊朗患者三阴性乳腺癌的生存率
Acta Med Iran. 2013 Sep 9;51(8):560-6.
9
Risk factors for breast cancer in Iranian women: a hospital-based case-control study in tabriz, iran.伊朗女性乳腺癌的危险因素：伊朗大不里士基于医院的病例对照研究。
J Breast Cancer. 2014 Sep;17(3):236-43. doi: 10.4048/jbc.2014.17.3.236. Epub 2014 Sep 30.
10
The impact of hormone receptor status on survival and recurrence of HER2-positive breast cancers in standard adjuvant setting: A retrospective study in Tehran, Iran.激素受体状态对标准辅助治疗中HER2阳性乳腺癌生存及复发的影响：伊朗德黑兰的一项回顾性研究
J Pak Med Assoc. 2020 Jan;70(1):11-16. doi: 10.5455/JPMA.290165.

引用本文的文献

1
Bayesian Spatial Analysis of the Incidence Rate of Patients with Breast Cancer in Southern Iran.伊朗南部乳腺癌患者发病率的贝叶斯空间分析
Iran J Med Sci. 2025 May 1;50(5):316-323. doi: 10.30476/ijms.2024.102475.3546. eCollection 2025 May.
2
The association between adiposity indices and the odds of breast cancer based on findings from a case control study.基于一项病例对照研究的结果，肥胖指数与乳腺癌发病几率之间的关联。
Sci Rep. 2025 May 22;15(1):17754. doi: 10.1038/s41598-025-02392-2.
3
Natural killer cell subsets and their functional molecules in peripheral blood of the patients with breast cancer.

本文引用的文献

1
Regional recurrence in the era of sentinel lymph node biopsy.前哨淋巴结活检时代的区域复发
Am J Surg. 2015 Dec;210(6):1155-60; discussion 1160-1. doi: 10.1016/j.amjsurg.2015.09.001. Epub 2015 Sep 28.
2
Breast cancer statistics, 2015: Convergence of incidence rates between black and white women.乳腺癌统计数据，2015：黑人和白人女性发病率趋同。
CA Cancer J Clin. 2016 Jan-Feb;66(1):31-42. doi: 10.3322/caac.21320. Epub 2015 Oct 29.
3
Benefits and Harms of Breast Cancer Screening: A Systematic Review.乳腺癌筛查的获益与危害：系统评价。
乳腺癌患者外周血中自然杀伤细胞亚群及其功能分子。
Immun Inflamm Dis. 2024 Apr;12(4):e1255. doi: 10.1002/iid3.1255.
4
Global trends of cancer: The role of diet, lifestyle, and environmental factors.癌症的全球趋势：饮食、生活方式和环境因素的作用。
Cancer Innov. 2023 Jul 25;2(4):290-301. doi: 10.1002/cai2.76. eCollection 2023 Aug.
5
Prevalence of Androgen Receptor in Invasive Breast Cancer and Its Association with Clinicopathologic Features in East Azarbaijan Province of Iran: A Cross-Sectional Study.伊朗东阿塞拜疆省浸润性乳腺癌中雄激素受体的患病率及其与临床病理特征的关联：一项横断面研究
Int J Hematol Oncol Stem Cell Res. 2023 Jul 1;17(3):186-193. doi: 10.18502/ijhoscr.v17i3.13308.
6
Survival analysis of recurrent breast cancer patients using mix Bayesian network.使用混合贝叶斯网络对复发性乳腺癌患者进行生存分析。
Heliyon. 2023 Sep 21;9(10):e20360. doi: 10.1016/j.heliyon.2023.e20360. eCollection 2023 Oct.
7
The effect of educational intervention based on the PEN-3 model on breast cancer screening behaviors.基于 PEN-3 模型的教育干预对乳腺癌筛查行为的影响。
Front Public Health. 2023 Aug 1;11:1123888. doi: 10.3389/fpubh.2023.1123888. eCollection 2023.
8
Latent Toxoplasmosis among Breast Cancer Patients in Jahrom, South of Iran.伊朗南部贾赫罗姆乳腺癌患者中的潜伏性弓形虫病
Int J Breast Cancer. 2023 Jul 22;2023:4792260. doi: 10.1155/2023/4792260. eCollection 2023.
9
Applications of different machine learning approaches in prediction of breast cancer diagnosis delay.不同机器学习方法在乳腺癌诊断延迟预测中的应用
Front Oncol. 2023 Feb 16;13:1103369. doi: 10.3389/fonc.2023.1103369. eCollection 2023.
10
Neoadjuvant VS adjuvant chemotherapy in patients with locally advanced breast cancer; a retrospective cohort study.局部晚期乳腺癌患者新辅助化疗与辅助化疗的比较：一项回顾性队列研究。
Ann Med Surg (Lond). 2022 Nov 15;84:104921. doi: 10.1016/j.amsu.2022.104921. eCollection 2022 Dec.
JAMA. 2015 Oct 20;314(15):1615-34. doi: 10.1001/jama.2015.13183.
4
[Lobular invasive breast cancer prognostic factors: About 940 patients].小叶浸润性乳腺癌的预后因素：约940例患者
Gynecol Obstet Fertil. 2015 Nov;43(11):712-7. doi: 10.1016/j.gyobfe.2015.09.007. Epub 2015 Oct 16.
5
Breast conservative surgery and local recurrence.保乳手术与局部复发
Breast. 2015 Nov;24 Suppl 2:S100-7. doi: 10.1016/j.breast.2015.07.024. Epub 2015 Oct 1.
6
Hormone Replacement Therapy and Risk of Breast Cancer in Korean Women: A Quantitative Systematic Review.激素替代疗法与韩国女性患乳腺癌的风险：一项定量系统评价
J Prev Med Public Health. 2015 Sep;48(5):225-30. doi: 10.3961/jpmph.15.046. Epub 2015 Sep 16.
7
Hormonal contraceptives and hormone replacement therapy as a possible factor of breast cancer.激素避孕药和激素替代疗法作为乳腺癌的一个可能因素。
Rocz Panstw Zakl Hig. 2015;66(3):269-74.
8
European Code against Cancer 4th Edition: Medical exposures, including hormone therapy, and cancer.《欧洲抗癌法典》第4版：医疗照射，包括激素治疗与癌症
Cancer Epidemiol. 2015 Dec;39 Suppl 1:S107-19. doi: 10.1016/j.canep.2015.08.003. Epub 2015 Sep 26.
9
Conservative surgery for multifocal/multicentric breast cancer.多灶性/多中心性乳腺癌的保守性手术
Breast. 2015 Nov;24 Suppl 2:S96-9. doi: 10.1016/j.breast.2015.07.023. Epub 2015 Aug 21.
10
Current approaches in treatment of triple-negative breast cancer.三阴性乳腺癌的当前治疗方法。
Cancer Biol Med. 2015 Jun;12(2):106-16. doi: 10.7497/j.issn.2095-3941.2015.0030.